MIN 117

Drug Profile

MIN 117

Alternative Names: MIN-117; Wf-516; WF516

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Antidepressants; Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Dopamine uptake inhibitors; Serotonin 1A receptor antagonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 26 Sep 2016 US FDA accepts IND application for MIN 117 in Major depressive disorder
  • 26 Sep 2016 Minerva Neurosciences plans clinical trials in Major depressive disorder in USA
  • 01 Jun 2016 Minerva Neurosciences completes a phase IIa trial in Major depressive disorder in Latvia, Poland and Finland (EudraCT2015-000306-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top